Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype.

Journal of thrombosis and haemostasis : JTH - 1 Feb 2005

Ray K K, Francis S, Crossman D C

Abstract excerpt

OBJECTIVES: Our aim was to determine a pharmacogenomic approach to heparin use in non-ST elevation acute coronary syndromes, specifically the impact of interleukin (IL)-1 receptor antagonist polymorphisms upon von Willebrand factor (vWF) responses to unfractionated heparin (UFH) and low molecular weight heparin (LMWH). BACKGROUND: In acute coronary syndromes (ACS), identification of specific biological or genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coronary Disease

Share to Electrocardiography

Share to Heparin

Share to Interleukin 1 Receptor Antagonist Protein

Share to Sialoglycoproteins

Share to von Willebrand Factor

Source

Identifiers

PMID: 15670034
DOI: 10.1111/j.1538-7836.2005.01125.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: the role of interleukin-1 receptor antagonist genotype.PMID 15670034Read ↗

Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes.Semantic proximity Read ↗

Haplotypes of the interleukin-1 receptor antagonist gene, interleukin-1 receptor antagonist mRNA levels and the risk of myocardial infarction.Semantic proximity Read ↗

Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events.Semantic proximity Read ↗

A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction.Semantic proximity Read ↗

Interleukin 1 receptor antagonist polymorphisms are associated with the risk of developing acute coronary syndrome in Mexicans.Semantic proximity Read ↗

Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.Semantic proximity Read ↗

Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome?Semantic proximity Read ↗

A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.